[Cutaneous drug eruption at hospital in Bamako].

Mali Med

Service de dermatologie, CHU-Gabriel Toure Bamako, Mali.

Published: November 2012

Introduction: The incidences of cutaneous drug eruption constitute a real public health problem.

Objective: The aim of this study was to describe the cutaneous drug eruption in Gabriel Touré Hospital in Bamako.

Material And Method: This is a prospective longitudinal study from 1 July 2005 to August 31, 2006. The study included patients with a lesion cutaneous Contemporary taking medication, without other cause and consent.

Results: We included 61 cases of toxdermies. The mean age was 28 ± 14.8 years with extremes of 18 and 77 years. The sex ratio was 2.4 for women. Self-medication was most often found in 51% of cases. The fixed drug eruption (EPF) with 26 cases (30.6%); acne with 23 cases (27%), erythema multiforme with 14 cases (16.5%) are the predominant manifestations toxidermy. The causative drugs are molecules with 12.6% with analgesics, NSAIDs with 12.6%, 13.6% with ARVs; sulfonamides with 9.5% with 7.4% beta-lactam; anticonvulsants with 5.2%. The therapeutic management was simple for minor forms. Severe forms have been hospitalized and often the help of intensive care and ophthalmology. Mortality was 2.3%.

Conclusion: The toxidermy exist in Mali with a frequency more and more increasing. We recommend the systematic toxidermy consultations especially among HIV patients in Mali.

Download full-text PDF

Source

Publication Analysis

Top Keywords

drug eruption
16
cutaneous drug
8
cases
5
[cutaneous drug
4
eruption
4
eruption hospital
4
hospital bamako]
4
bamako] introduction
4
introduction incidences
4
incidences cutaneous
4

Similar Publications

Acute generalized exanthematous pustulosis (AGEP) is a rare drug eruption characterized by the rapid occurrence of many sterile, non-follicular pustules, neutrophilic leukocytosis, high fever and spontaneous resolution usually within two weeks. The distribution of rash predilection in the trunk and intertriginous regions. In treatment, the causative drug must be initially discontinued.

View Article and Find Full Text PDF

Erlotinib-induced Perioral Lesions Resembling Scleroderma.

Acta Dermatovenerol Croat

November 2024

Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.

View Article and Find Full Text PDF

Phototoxic reaction to oral terbinafine due to Tinea capitis in a child.

Acta Dermatovenerol Croat

November 2024

Prof. Ana Bakija-Konsuo, MD, PhD, Clinic for Dermatovenerology CUTIS, Vukovarska 22, Dubrovnik, Croatia;

We report the case of an 18-month-old boy who developed a phototoxic skin reaction to terbinafine on his scalp, ears, and face in the form of disseminated erythematous plaques, which resembled subacute lupus erythematosus (SCLE) in their clinical presentation. Skin changes appeared a short time after the boy was exposed to sunlight during the period of time when he was treated with oral terbinafine due to Microsporum canis fungal scalp infection. Tinea capitis is a common dermatophyte infection primarily affecting prepubertal children (1).

View Article and Find Full Text PDF

Diagnosis, Investigation and Management of Non-immediate (Type IV) Cutaneous Adverse Drug Reactions.

Acta Dermatovenerol Croat

November 2024

Vesna Vukičević Lazarević, MD Special Hospital for Pulmonary Diseases, Rockefellerova 3, 10000 Zagreb, Croatia;

Pathophysiologically, drug hypersensitive reactions (DHRs) are classified into four types: type I, immediate reactions, and types II, III, and IV, non-immediate reactions. They are further categorized as severe or non-severe based on clinical severity. Genetic predisposition and viral reactivation are cofactors of severe DHR type IV.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!